Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

HTR2B

  • Luc Maroteaux
  • Anne Roumier
  • Stéphane Doly
  • Silvina Laura Diaz
  • Arnauld Belmer
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_286

Synonyms

Historical Background

Because of its exquisite sensitivity to serotonin, the rat stomach fundus was used as a bioassay for serotonin before the development of more quantitative analytical assays for this biogenic amine (Vane 1957). Although the potency for the contractile effects of serotonin has been known for long time, the receptors mediating such a response have eluded definitive characterization for long time. Pharmacological studies attempting to characterize the contractile serotonergic receptor in the rat stomach fundus documented the similarity to the 5-HT2C receptor. In the absence of detectable 5-HT2C receptor mRNA in the rat stomach fundus, only molecular cloning allowed the identification of a new receptor in 1992 in rat and mouse (Foguet et al. 1992; Kursar et al. 1992; Loric et al. 1992; Wainscott et al. 1993)...

This is a preview of subscription content, log in to check access.

References

  1. Aira Z, Buesa I, Salgueiro M, Bilbao J, Aguilera L, Zimmermann M, Azkue JJ. Subtype-specific changes in 5-HT receptor-mediated modulation of C fibre-evoked spinal field potentials are triggered by peripheral nerve injury. Neuroscience. 2010;168(3):831–41.PubMedCrossRefGoogle Scholar
  2. Aira Z, Buesa I, García Del Caño G, Salgueiro M, Mendiable N, Mingo J, Azkue JJ. Selective impairment of spinal mu-opioid receptor mechanism by plasticity of serotonergic facilitation mediated by 5-HT2A and 5-HT2B receptors. Pain. 2012;153(7):1418–25.PubMedCrossRefGoogle Scholar
  3. Aira Z, Buesa I, García Del Caño G, Bilbao J, Doñate F, Zimmermann M, Azkue JJ. Transient, 5-HT2B receptor-mediated facilitation in neuropathic pain: up-regulation of PKCγ and engagement of the NMDA receptor in dorsal horn neurons. Pain. 2013;154(9):1865–77.PubMedCrossRefGoogle Scholar
  4. Aira Z, Buesa I, Rada D, Gómez-Esteban JC, Azkue JJ. Coupling of serotonergic input to NMDA receptor-phosphorylation following peripheral nerve injury via rapid, synaptic up-regulation of ND2. Exp Neurol. 2014;255C:86–95.CrossRefGoogle Scholar
  5. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6(9):826–9.PubMedCrossRefGoogle Scholar
  6. Asada M, Ebihara S, Yamanda S, Niu K, Okazaki T, Sora I, Arai H. Depletion of serotonin and selective inhibition of 2B receptor suppressed tumor angiogenesis by inhibiting endothelial nitric oxide synthase and extracellular signal-regulated kinase 1/2 phosphorylation. Neoplasia. 2009;11(4):408–17.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Auclair AL, Cathala A, Sarrazin F, Depoortère R, Piazza PV, Newman-Tancredi A, Spampinato U. The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem. 2010;114(5):1323–32.PubMedGoogle Scholar
  8. Audia JE, Evrard DA, Murdoch GR, Droste JJ, Nissen JS, Schenck KW, Cohen ML. Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5-HT2B) contractile receptor in the rat stomach fundus. J Med Chem. 1996;39:2773–80.PubMedCrossRefGoogle Scholar
  9. Ayme-Dietrich E, Lawson R, Gasser B, Dallemand R, Bischoff N, Monassier L. Mitral bioprosthesis hypertrophic scaring and native aortic valve fibrosis during benfluorex therapy. Fundam Clin Pharmacol. 2012;26(2):215–8.PubMedCrossRefGoogle Scholar
  10. Bai C-F, Liu J-C, Zhao R, Cao W, Liu S-B, Zhang X-N, Zhao M-G. Role of 5-HT2B receptor in cardiomyocyte apoptosis of norepinephrine-induced cardiomyopathy model in rats. Clin Exp Pharmacol Physiol. 2010;37:e145–51.PubMedCrossRefGoogle Scholar
  11. Banas S, Doly S, Boutourlinsky K, Diaz S, Belmer A, Callebert J, Maroteaux L. Deconstructing antiobesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects. Neuropsychopharmacology. 2011;36:423–33.PubMedCrossRefGoogle Scholar
  12. Baudry A, Bitard J, Mouillet-Richard S, Locker M, Poliard A, Launay J-M, Kellermann O. The serotonergic 5-HT2B receptor controls tissue non-specific alkaline phosphatase activity in osteoblasts via eicosanoids and phosphatidylinositol-specific phospholipase C. J Biol Chem. 2010;285(34):26066–73.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Becamel C, Figge A, Poliak S, Dumuis A, Peles E, Bockaert J, Ullmer C. Interaction of serotonin 5-HT2C receptors with PDZ10 of the multi PDZ protein MUPP1. J Biol Chem. 2001;276(16):12974–82.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Belmer A, Doly S, Setola V, Banas SM, Moutkine I, Boutourlinsky K, Maroteaux L. Role of the N-terminal region in G-Protein coupled receptor functions: negative modulation revealed by 5-HT2B receptor polymorphisms. Mol Pharmacol. 2014;85(1):127–38.PubMedCrossRefGoogle Scholar
  15. Bevilacqua L, Doly S, Kaprio J, Yuan Q, Tikkanen R, Paunio T, Goldman D. A population-specific HTR2B stop codon predisposes to severe impulsivity. Nature. 2010;468(8):1061–6.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Bhasin N, Kernick E, Luo X, Seidel HE, Weiss ER, Lauder JM. Differential regulation of chondrogenic differentiation by the serotonin2B receptor and retinoic acid in the embryonic mouse hindlimb. Dev Dyn. 2004;230(2):201–9.PubMedCrossRefGoogle Scholar
  17. Bliziotes MM, Eshleman AJ, Zhang XW, Wiren KM. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone. 2001;29(5):477–86.PubMedCrossRefGoogle Scholar
  18. Bonaventure P, Guo H, Tian B, Liu X, Bittner A, Roland B, Erlander MG. Nuclei and subnuclei gene expression profiling in mammalian brain. Brain Res. 2002;943(1):38–47.PubMedCrossRefGoogle Scholar
  19. Bonhaus DW, Bach C, DeSouza A, Salazar FHR, Matsuoka BD, Zuppan P, Eglen RM. The pharmacology and distribution of human 5-hydroxytryptamine 2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol. 1995;115:622–8.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C, Dawson M, Martin GR. RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br J Pharmacol. 1999;127(5):1075–82.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Bulenger S, Marullo S, Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci. 2005;26(3):131–7.PubMedCrossRefGoogle Scholar
  22. Cervantes-Durán C, Vidal-Cantú GC, Barragán-Iglesias P, Pineda-Farias JB, Bravo-Hernández M, Murbartián J, Granados-Soto V. Role of peripheral and spinal 5-HT(2B) receptors in formalin-induced nociception. Pharmacol Biochem Behav. 2012;102(1):30–5.PubMedCrossRefGoogle Scholar
  23. Chabbi-Achengli Y, Launay J-M, Maroteaux L, De Vernejoul MC, Collet C. Serotonin 2B receptor (5-HT2B R) signals through prostacyclin and PPAR-ß/δ in osteoblasts. PLoS One. 2013;8(9):e75783.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol. 2008;44(1):14–30.PubMedCrossRefGoogle Scholar
  25. Choi D-S, Maroteaux L. Immunohistochemical localisation of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain. FEBS Lett. 1996;391:45–51.PubMedCrossRefGoogle Scholar
  26. Choi D-S, Birraux G, Launay J-M, Maroteaux L. The human serotonin 5-HT2B receptor: pharmacological link between 5-HT2 and 5-HT1D receptors. FEBS L. 1994;352:393–9.CrossRefGoogle Scholar
  27. Choi D-S, Ward S, Messaddeq N, Launay J-M, Maroteaux L. 5-HT2B receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardiac cells. Development. 1997;124:1745–55.PubMedGoogle Scholar
  28. Cohen ML, Schenck KW, Mabry TE, Nelson DL, JE A. LY272015, a potent, selective and orally active 5-HT2B receptor antagonist. J Serv Res. 1996;3:131–44.Google Scholar
  29. Collet C, Schiltz C, Geoffroy V, Maroteaux L, Launay J-M, de Vernejoul M-C. The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J. 2008;22(2):418–27.PubMedCrossRefGoogle Scholar
  30. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581–8.PubMedCrossRefGoogle Scholar
  31. Corominas R, Sobrido MJ, Ribasés M, Cuenca-León E, Blanco-Arias P, Narberhaus B, Cormand B. Association study of the serotoninergic system in migraine in the Spanish population. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(1):177–84.PubMedGoogle Scholar
  32. Cremer SE, Moesgaard SG, Rasmussen CE, Zois NE, Falk T, Reimann MJ, et al. Alpha-smooth muscle actin and serotonin receptors 2A and 2B in dogs with myxomatous mitral valve disease. Res Vet Sci. 2015a;100:197–206.PubMedCrossRefGoogle Scholar
  33. Cremer SE, Zois NE, Moesgaard SG, Ravn N, Cirera S, Honge JL, Olsen LH. Serotonin markers show altered transcription levels in an experimental pig model of mitral regurgitation. Vet J. 2015b;203(2):192–8.PubMedCrossRefGoogle Scholar
  34. Cussac D, Newman-Tancredi A, Quentric Y, Carpentier N, Poissonnet G, Parmentier JG, Millan MJ. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. Naunyn Schmiedeberg's Arch Pharmacol. 2002;365(3):242–52.CrossRefGoogle Scholar
  35. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008;594(1–3):32–8.PubMedCrossRefGoogle Scholar
  36. Dawson P, Opacka-Juffry J, Moffatt JD, Daniju Y, Dutta N, Ramsey J, Davidson C. The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:57–63.CrossRefGoogle Scholar
  37. Dees C, Akhmetshina A, Reich N, Jüngel A, Beyer C, Krönke G, Distler JHW. Platelet derived serotonin links vascular disease and tissue fibrosis. J Exp Med. 2011;208(5):961–72.PubMedPubMedCentralCrossRefGoogle Scholar
  38. Diaz SL, Doly S, Narboux-Nême N, Fernandez S, Mazot P, Banas S, Maroteaux L. 5-HT2B receptors are required for serotonin-selective antidepressant actions. Mol Psychiatry. 2012;17:154–63.PubMedCrossRefGoogle Scholar
  39. Diaz SL, Narboux-Nême N, Boutourlinsky K, Doly S, Maroteaux L. Mice lacking the serotonin 5-HT2B receptor as an animal model of resistance to selective serotonin reuptake inhibitors antidepressants. Eur Neuropsychopharmacol. 2016;26(2):265–79.PubMedCrossRefGoogle Scholar
  40. Dizeyi N, Bjartell A, Hedlund P, Tasken KA, Gadaleanu V, Abrahamsson PA. Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur Urol. 2005;47(6):895–900.PubMedCrossRefGoogle Scholar
  41. Doly S, Valjent E, Setola V, Callebert J, Herve D, Launay JM, Maroteaux L. Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci. 2008;28(11):2933–40.PubMedCrossRefGoogle Scholar
  42. Doly S, Bertran-Gonzalez J, Callebert J, Bruneau A, Banas SM, Belmer A, Maroteaux L. Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice. PLoS One. 2009;4(11):e7952.PubMedPubMedCentralCrossRefGoogle Scholar
  43. Dumitrascu R, Kulcke C, Königshoff M, Kouri F, Yang X, Morrell N, Pullamsetti SS. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J. 2011;37(5):1104–18.PubMedCrossRefGoogle Scholar
  44. Ebrahimkhani M, Oakley F, Murphy L, Mann J, Moles A, Perugorria M, Mann D. Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease. Nat Med. 2011;17(12):1668–73.PubMedPubMedCentralCrossRefGoogle Scholar
  45. Ellis ES, Byrne C, Murphy OE, Tilford NS, Baxter GS. Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein. Br J Pharmacol. 1995;114(2):400–4.PubMedPubMedCentralCrossRefGoogle Scholar
  46. Fabre A, Marchal-Sommé J, Marchand-Adam S, Quesnel C, Borie R, Dehoux M, Crestani B. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur Respir J. 2008;32(2):426–36.PubMedCrossRefGoogle Scholar
  47. Fatima S, Shi X, Lin Z, Chen G-q, Pan X-h, Wu JC-Y, Bian ZX. 5-Hydroxytryptamine promotes hepatocellular carcinoma proliferation by influencing β-catenin. Mol Oncol. 2016;10(2):195–212.PubMedCrossRefGoogle Scholar
  48. Fernandez-Ranvier GG, Weng J, Yeh RF, Khanafshar E, Suh I, Barker C, Kebebew E. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg. 2008;143(9):841–6.PubMedCrossRefGoogle Scholar
  49. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Robertson DW. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000;57(1):75–81.PubMedGoogle Scholar
  50. Foguet M, Hoyer D, Pardo LA, Parekh A, Kluxen FW, Kalkman HO, Lübbert H. Cloning and functional characterization of the rat stomach fundus serotonin receptor. EMBO J. 1992;11(9):3481–7.PubMedPubMedCentralCrossRefGoogle Scholar
  51. Glusa E, Pertz HH. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT2B receptors. Br J Pharmacol. 2000;130(3):692–8.PubMedPubMedCentralCrossRefGoogle Scholar
  52. Helton LA, Thor KB, Baez M. 5-Hydroxytryptamine2A, 5-hydroxytryptamine2B, and 5-hydroxytryptamine2C receptor mRNA expression in the spinal cord of rat, cat, monkey and human. Neuroreport. 1994;5(18):2617–20.PubMedCrossRefGoogle Scholar
  53. Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis. 1996;5(2):235–7.PubMedGoogle Scholar
  54. Hirai T, Tokumo K, Tsuchiya D, Nishio H. Expression of mRNA for 5-HT2 receptors and proteins related to inactivation of 5-HT in mouse osteoblasts. J Pharmacol Sci. 2009;109(2):319–23.PubMedCrossRefGoogle Scholar
  55. Hodge JM, Wang Y, Berk M, Collier FM, Fernandes TJ, Constable MJ, Williams LJ. Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry. 2013;74(1):32–9.PubMedCrossRefGoogle Scholar
  56. Holohean AM, Hackman JC. Mechanisms intrinsic to 5-HT2B receptor-induced potentiation of NMDA receptor responses in frog motoneurones. Br J Pharmacol. 2004;143(3):351–60.PubMedPubMedCentralCrossRefGoogle Scholar
  57. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Lang AE. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004;19(6):656–62.PubMedCrossRefGoogle Scholar
  58. Iizuka N, Oka M, Yamada-Okabe H, Hamada K, Nakayama H, Mori N, Hamamoto Y. Molecular signature in three types of hepatocellular carcinoma with different viral origin by oligonucleotide microarray. Int J Oncol. 2004;24(3):565–74.PubMedGoogle Scholar
  59. Iversen L, Gibbons S, Treble R, Setola V, Huang X-P, Roth BL. Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol. 2013;700(1–3):147–51.PubMedCrossRefGoogle Scholar
  60. Jaffré F, Callebert J, Sarre A, Etienne N, Nebigil CG, Launay JM, Monassier L. Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1 beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation. 2004;110:969–74.PubMedCrossRefGoogle Scholar
  61. Jaffre F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, Maroteaux L. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res. 2009;104(1):113–23.PubMedCrossRefGoogle Scholar
  62. Jerman JC, Brough SJ, Gager T, Wood M, Coldwell MC, Smart D, Middlemiss DN. Pharmacological characterisation of human 5-HT2 receptor subtypes. Eur J Pharmacol. 2001;414(1):23–30.PubMedCrossRefGoogle Scholar
  63. Johnson KW, Nelson DL, Dieckman DK, Wainscott DB, Lucaites VL, Audia JE, Phebus LA. Neurogenic dural protein extravasation induced by meta-chlorophenylpiperazine (mCPP) involves nitric oxide and 5-HT2B receptor activation. Cephalalgia. 2003;23(2):117–23.PubMedCrossRefGoogle Scholar
  64. Kelly CR, Sharif NA. Pharmacological evidence for a functional serotonin-2B receptor in a human uterine smooth muscle cell line. J Pharmacol Exp Ther. 2006;317(3):1254–61.PubMedCrossRefGoogle Scholar
  65. Kim H, Toyofuku Y, Lynn FC, Chak E, Uchida T, Mizukami H, German MS. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med. 2010;16(7):804–8.PubMedPubMedCentralCrossRefGoogle Scholar
  66. Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Szombathelyi Z. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328–40.PubMedCrossRefGoogle Scholar
  67. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M. Pharmacological characterisation of the agonist radioligand binding site of 5-HT2A, 5-HT2B and 5-HT2C receptors. Naunyn Schmiedeberg's Arch Pharmacol. 2004;370(2):114–23.CrossRefGoogle Scholar
  68. Kolodziejczak M, Bechade C, Gervasi N, Irinopoulou T, Banas SM, Cordier C, Maroteaux L. Serotonin modulates developmental microglia via 5-HT2B receptors: potential implication during synaptic refinement of retinogeniculate projections. ACS Chem Neurosci. 2015;6(7):1219–30.PubMedCrossRefGoogle Scholar
  69. Königshoff M, Dumitrascu R, Udalov S, Amarie OV, Reiter R, Grimminger F, Eickelberg O. Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention. Thorax. 2010;65(11):949–55.PubMedCrossRefGoogle Scholar
  70. Kopparapu PK, Tinzl M, Anagnostaki L, Persson JL, Dizeyi N. Expression and localization of serotonin receptors in human breast cancer. Anticancer Res. 2013;33(2):363–70.PubMedGoogle Scholar
  71. Krabbe G, Matyash V, Pannasch U, Mamer L, Boddeke HWGM, Kettenmann H. Activation of serotonin receptors promotes microglial injury-induced motility but attenuates phagocytic activity. Brain Behav Immun. 2012;26(3):419–28.PubMedCrossRefGoogle Scholar
  72. Kursar JD, Nelson DL, Wainscott DB, Cohen ML, Baez M. Molecular cloning, functional expression, and pharmacological characterisation of a novel serotonin (5-Hydroxytryptamine2F) from rat stomach fundus. Mol Pharmacol. 1992;42:549–57.PubMedGoogle Scholar
  73. Kursar JD, Nelson DL, Wainscott D, Baez M. Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol Pharmacol. 1994;46:227–34.PubMedGoogle Scholar
  74. Lampron A, Bourdeau I, Hamet P, Tremblay J, Lacroix A. Whole genome expression profiling of glucose-dependent insulinotropic peptide (GIP)- and adrenocorticotropin-dependent adrenal hyperplasias reveals novel targets for the study of GIP-dependent Cushing’s syndrome. J Clin Endocrinol Metab. 2006;91(9):3611–8.PubMedCrossRefGoogle Scholar
  75. Launay J-M, Birraux G, Bondoux D, Callebert J, Choi D-S, Loric S, Maroteaux L. Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J Biol Chem. 1996;271:3141–7.PubMedCrossRefGoogle Scholar
  76. Launay JM, Hervé P, Peoc’h K, Tournois C, Callebert J, Nebigil C, Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002;8:1129–35.PubMedCrossRefGoogle Scholar
  77. Launay J-M, Hervé P, Callebert J, Mallat Z, Collet C, Doly S, Maroteaux L. Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. Blood. 2012;119(7):1772–80.PubMedCrossRefGoogle Scholar
  78. Li T, Weng S-G, Leng X-S, Peng J-R, Wei Y-H, Mou D-C, Wang W-X. Effects of 5-hydroxytamine and its antagonists on hepatic stellate cells. Hepatobiliary Pancreat Dis Int. 2006;5(1):96–100.PubMedGoogle Scholar
  79. Liang YJ, Lai LP, Wang BW, Juang SJ, Chang CM, Leu JG, Shyu KG. Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-kappaB in cardiomyocytes. Cardiovasc Res. 2006;72(2):303–12.PubMedCrossRefGoogle Scholar
  80. Liang C, Chen W, Zhi X, Ma T, Xia X, Liu H, Liang T. Serotonin promotes the proliferation of serum-deprived hepatocellular carcinoma cells via upregulation of FOXO3a. Mol Cancer. 2013;12:14.PubMedPubMedCentralCrossRefGoogle Scholar
  81. Lin S-Y, Chang W-J, Lin C-S, Huang C-Y, Wang H-F, Sun W-H. Serotonin receptor 5-HT2B mediates serotonin-induced mechanical hyperalgesia. J Neurosci. 2011;31(4):1410–8.PubMedCrossRefGoogle Scholar
  82. Liu W, Wacker D, Gati C, Han GW, James D, Wang D, Cherezov V. Serial femtosecond rystallography of G protein-coupled receptors. Science. 2013;342(6165):1521–4.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Locker M, Bitard J, Collet C, Poliard A, Mutel V, Launay JM, Kellermann O. Stepwise control of osteogenic differentiation by 5-HT2B receptor signaling: nitric oxide production and phospholipase A2 activation. Cell Signal. 2006;18(5):628–39.PubMedCrossRefGoogle Scholar
  84. Loric S, Launay J-M, Colas J-F, Maroteaux L. New mouse 5-HT2-like receptor: expression in brain, heart, and intestine. FEBS L. 1992;312:203–7.CrossRefGoogle Scholar
  85. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001;61(15):5692–6.PubMedGoogle Scholar
  86. Manivet P, Mouillet-Richard S, Callebert J, Nebigil CG, Maroteaux L, Hosoda S, Launay J-M. PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor. J Biol Chem. 2000;275:9324–31.PubMedCrossRefGoogle Scholar
  87. Martí-Solano M, Sanz F, Pastor M, Selent J. A dynamic view of molecular switch behavior at serotonin receptors: implications for functional selectivity. PLoS One. 2014;9(10):e109312.PubMedPubMedCentralCrossRefGoogle Scholar
  88. Matsuda A, Suzuki Y, Honda G, Muramatsu S, Matsuzaki O, Nagano Y, Sugano S. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene. 2003;22(21):3307–18.PubMedPubMedCentralCrossRefGoogle Scholar
  89. McCorvy JD, Roth BL. Structure and function of serotonin G protein-coupled receptors. Pharmacol Ther. 2015;150:129–42.PubMedPubMedCentralCrossRefGoogle Scholar
  90. McDevitt RA, Neumaier JF. Regulation of dorsal raphe nucleus function by serotonin autoreceptors: a behavioral perspective. J Chem Neuroanat. 2011;41(4):234–46.PubMedPubMedCentralCrossRefGoogle Scholar
  91. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954–64.PubMedCrossRefGoogle Scholar
  92. Monassier L, Laplante MA, Jaffre F, Bousquet P, Maroteaux L, de Champlain J. Serotonin 5-HT2B receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice. Hypertension. 2008;52:301–7.PubMedCrossRefGoogle Scholar
  93. Nebigil CG, Choi D-S, Dierich A, Hickel P, Le Meur M, Messaddeq N, Maroteaux L. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A. 2000a;97:9508–13.PubMedPubMedCentralCrossRefGoogle Scholar
  94. Nebigil CG, Launay J-M, Hickel P, Tournois C, Maroteaux L. 5-Hydroxytryptamine 2B receptor regulates cell-cycle progression: cross talk with tyrosine kinase pathways. Proc Natl Acad Sci U S A. 2000b;97(6):2591–6.PubMedPubMedCentralCrossRefGoogle Scholar
  95. Nebigil CG, Etienne N, Messaddeq N, Maroteaux L. Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2B-receptor signaling. FASEB J. 2003;17(10):1373–5.PubMedCrossRefGoogle Scholar
  96. Nelson DL, Lucaites VL, Wainscott DB, RA G. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors. Naunyn Schmiedeberg's Arch Pharmacol. 1999;359(1):1–6.CrossRefGoogle Scholar
  97. Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, PA C. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res. 2008;68(13):5152–8.PubMedCrossRefGoogle Scholar
  98. O’Mahony SM, Bulmer DC, Coelho A-M, Fitzgerald P, Bongiovanni C, Lee K, Cryan JF. 5-HT2B receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction. Neurogastroenterol Motil. 2010;22(5):573–8.PubMedCrossRefGoogle Scholar
  99. Oh CK, Drescher MJ, Hatfield JS, DG D. Selective expression of serotonin receptor transcripts in the mammalian cochlea and its subdivisions. Brain Res Mol Brain Res. 1999;70(1):135–40.PubMedCrossRefGoogle Scholar
  100. Ohashi-Doi K, Himaki D, Nagao K, Kawai M, Gale JD, Furness JB, Kurebayashi Y. A selective, high affinity 5-HT2B receptor antagonist inhibits visceral hypersensitivity in rats. Neurogastroenterol Motil. 2009;22(2):e69–76.PubMedCrossRefGoogle Scholar
  101. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12(4):461–8.PubMedPubMedCentralCrossRefGoogle Scholar
  102. Osredkar D, Krzan M. Expression of serotonin receptor subtypes in rat brain and astrocyte cell cultures: an age-and tissue-dependent process. Period Biol. 2009;111(1):129–35.Google Scholar
  103. Pai V, Marshall A, Hernandez L, Buckley A, Horseman N. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res. 2009;11(6):R81.PubMedPubMedCentralCrossRefGoogle Scholar
  104. Papageorgiou A, Denef C. Stimulation of growth hormone release by 5-hydroxytryptamine (5-HT) in cultured rat anterior pituitary cell aggregates: evidence for mediation by 5-HT2B, 5-HT7, 5-HT1B, and ketanserin-sensitive receptors. Endocrinology. 2007;148(9):4509–22.PubMedCrossRefGoogle Scholar
  105. Park K-S, Sin P-J, Lee DH, Cha S-K, Kim M-J, Kim N-H, Kong ID. Switching-on of serotonergic calcium signaling in activated hepatic stellate cells. World J Gastroenterol. 2011;17(2):164–73.PubMedPubMedCentralCrossRefGoogle Scholar
  106. Pietri M, Schneider B, Mouillet-Richard S, Ermonval M, Mutel V, Launay J-M, Kellermann O. Reactive oxygen species-dependent TNF-alpha converting enzyme activation trough stimulation of 5-HT2B and alpha1D autoreceptors in neuronal cells. FASEB J. 2005;19:1078–87.PubMedCrossRefGoogle Scholar
  107. Pitychoutis P, Belmer A, Moutkine I, Adrien J, Maroteaux L. Mice lacking the serotonin Htr2B receptor gene present an antipsychotic-sensitive schizophrenic-like phenotype. Neuropsychopharmacology. 2015;40(12):2764–73.PubMedPubMedCentralCrossRefGoogle Scholar
  108. Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Sheardown MJ. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol. 1999;128(1):13–20.PubMedPubMedCentralCrossRefGoogle Scholar
  109. Porvasnik SL, Germain S, Embury J, Gannon KS, Jacques V, Murray J, Al-Mousily F. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. J Pharmacol Exp Ther. 2010;334(2):364–72.PubMedCrossRefGoogle Scholar
  110. Rickli A, Kopf S, Hoener MC, Liechti ME. Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol. 2015;172(13):3412–25.PubMedPubMedCentralCrossRefGoogle Scholar
  111. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, Feldman JM. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995;92(4):790–5.PubMedCrossRefGoogle Scholar
  112. Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356(1):6–9.PubMedCrossRefGoogle Scholar
  113. Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan-Lluka LJ, Ramm GA, Mann DA. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol. 2006;169(3):861–76.PubMedPubMedCentralCrossRefGoogle Scholar
  114. Russell A, Banes A, Berlin H, Fink GD, Watts SW. 5-Hydroxytryptamine2B receptor function is enhanced in the N(omega)-Nitro-L-arginine hypertensive rat. J Pharmacol Exp Ther. 2002;303(1):179–87.PubMedCrossRefGoogle Scholar
  115. Sanden N, Thorlin T, Blomstrand F, Persson PA, Hansson E. 5-Hydroxytryptamine2B receptors stimulate Ca2+ increases in cultured astrocytes from three different brain regions. Neurochem Int. 2000;36(4–5):427–34.PubMedCrossRefGoogle Scholar
  116. Schmitz B, Ullmer C, Segelcke D, Gwarek M, Zhu X-R, Lübbert H. BF-1--a novel selective 5-HT2B receptor antagonist blocking neurogenic dural plasma protein extravasation in guinea pigs. Eur J Pharmacol. 2015;751:73–80.PubMedCrossRefGoogle Scholar
  117. Schmuck K, Ullmer C, Engels P, Lübbert H. Cloning and functionnal characterisation of the human 5-HT2B serotonin receptor. FEBS L. 1994;342:85–90.CrossRefGoogle Scholar
  118. Schmuck K, Ullmer C, Kalkman H, Probst A, Lübbert H. Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur J Neurosci. 1996;8:959–67.PubMedCrossRefGoogle Scholar
  119. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Roth BL. 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003;63(6):1223–9.PubMedCrossRefGoogle Scholar
  120. Shahid M, Walker GB, Zorn SH, Wong EHF. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharm. 2009;23(1):65–73.CrossRefGoogle Scholar
  121. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400–11.PubMedCrossRefGoogle Scholar
  122. Sharif NA, Senchyna M. Serotonin receptor subtype mRNA expression in human ocular tissues, determined by RT-PCR. Mol Vis. 2006;12:1040–7.PubMedGoogle Scholar
  123. Slominski A, Pisarchik A, Zbytek B, Tobin DJ, Kauser S, Wortsman J. Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J Cell Physiol. 2003;196(1):144–53.PubMedCrossRefGoogle Scholar
  124. Slominski A, Pisarchik A, Wortsman J. Expression of genes coding melatonin and serotonin receptors in rodent skin. Biochim Biophys Acta. 2004;1680(2):67–70.PubMedCrossRefGoogle Scholar
  125. Soll C, Jang JH, Riener M-O, Moritz W, Wild PJ, Graf R, Clavien P-A. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology. 2010;51(4):1244–54.PubMedCrossRefGoogle Scholar
  126. Soll C, Riener M-O, Oberkofler CE, Hellerbrand C, Wild PJ, Deoliveira ML, Clavien P-A. Expression of serotonin receptors in human hepatocellular cancer. Clin Cancer Res. 2012;18(21):5902–10.PubMedCrossRefGoogle Scholar
  127. Stefulj J, Jernej B, Cicin-Sain L, Rinner I, Schauenstein K. mRNA expression of serotonin receptors in cells of the immune tissues of the rat. Brain Behav Immun. 2000;14(3):219–24.PubMedCrossRefGoogle Scholar
  128. Su Y-S, Chiu Y-Y, Lin S-Y, Chen C-C, Sun W-H. Serotonin receptor 2B mediates mechanical hyperalgesia by regulating transient receptor potential vanilloid 1. J Mol Neurosci. 2016;59(1):113–25.PubMedCrossRefGoogle Scholar
  129. Svejda B, Kidd M, Giovinazzo F, Eltawil K, Gustafsson BI, Pfragner R, Modlin IM. The 5-HT2B receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer. 2010;116(12):2902–12.PubMedCrossRefGoogle Scholar
  130. Tadros SF, D’Souza M, Zettel ML, Zhu X, Lynch-Erhardt M, Frisina RD. Serotonin 2B receptor: upregulated with age and hearing loss in mouse auditory system. Neurobiol Aging. 2007;28(7):1112–23.PubMedCrossRefGoogle Scholar
  131. Tournois C, Mutel V, Manivet P, Launay JM, Kellermann O. Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line. Involvement of arachidonic acid metabolism. J Biol Chem. 1998;273(28):17498–503.PubMedCrossRefGoogle Scholar
  132. Tschentscher F, Husing J, Holter T, Kruse E, Dresen IG, Jockel KH, Zeschnigk M. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63(10):2578–84.PubMedGoogle Scholar
  133. Ullmer C, Schmuck K, Kalkman HO, Lübbert H. Expression of serotonin receptor mRNA in blood vessels. FEBS Lett. 1995;370:215–21.PubMedCrossRefGoogle Scholar
  134. Urtikova N, Berson N, Van Steenwinckel J, Doly S, Truchetto J, Maroteaux L, Conrath M. Antinociceptive effect of peripheral serotonin 5-HT(2B) receptor activation on neuropathic pain. Pain. 2012;153(6):1320–31.PubMedCrossRefGoogle Scholar
  135. van Gils W, Lodder EM, Mensink HW, Kiliç E, Naus NC, Brüggenwirth HT, de Klein A. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis. Invest Ophthalmol Vis Sci. 2008;49(10):4254–62.PubMedCrossRefGoogle Scholar
  136. Vane JR. A sensitive method for the assay of 5-hydroxytryptamine. Br J Pharmacol Chemother. 1957;12(3):344–9.PubMedPubMedCentralCrossRefGoogle Scholar
  137. Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, Stevens RC. Structural features for functional selectivity at serotonin receptors. Science. 2013;340(6132):615–9.PubMedPubMedCentralCrossRefGoogle Scholar
  138. Wainscott DB, Cohen ML, Schenck KW, Audia JE, Nissen JS, Baez M, Nelson DL. Pharmacological characteristics of the newly cloned rat 5-Hydroxytryptamine 2F receptor. Mol Pharmacol. 1993;43:419–26.PubMedGoogle Scholar
  139. Wainscott DB, Lucaites VL, Kursar JD, Baez M, Nelson DL. Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. J Pharmacol Exp Ther. 1996;276(2):720–7.PubMedGoogle Scholar
  140. Wang C, Jiang Y, Ma J, Wu H, Wacker D, Katritch V, Xu HE. Structural basis for molecular recognition at serotonin receptors. Science. 2013;340(6132):610–4.PubMedPubMedCentralCrossRefGoogle Scholar
  141. Watts SW, Fink GD. 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt- hypertensive rats. Am J Phys. 1999;276(3 Pt 2):H944–52.Google Scholar
  142. Watts SW, Baez M, Webb RC. The 5-hydroxytryptamine2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate- salt hypertensive rats. J Pharmacol Exp Ther. 1996;277(2):1103–13.PubMedGoogle Scholar
  143. Weir EK, Obreztchikova M, Hong Z. Fenfluramine: riddle or Rosetta stone? Eur Respir J. 2008;31(2):232–5.PubMedCrossRefGoogle Scholar
  144. West JD, Carrier EJ, Bloodworth NC, Schroer AK, Chen P, Ryzhova LM, Merryman WD. Serotonin 2B receptor antagonism prevents heritable pulmonary arterial hypertension. PLoS One. 2016;11(2):e0148657.PubMedPubMedCentralCrossRefGoogle Scholar
  145. Westbroek I, van Der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ. Expression of serotonin receptors in bone. J Biol Chem. 2001;276:28961–8.PubMedCrossRefGoogle Scholar
  146. Yabanoglu S, Akkiki M, Seguelas MH, Mialet-Perez J, Parini A, Pizzinat N. Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors. J Mol Cell Cardiol. 2009;46(4):518–25.PubMedCrossRefGoogle Scholar
  147. Yadav VK, Oury F, Suda N, Liu Z-W, Gao X-B, Confavreux C, Karsenty G. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 2009;138(5):976–89.PubMedPubMedCentralCrossRefGoogle Scholar
  148. Yan L, Chen X, Talati M, Nunley BW, Gladson S, Blackwell T, Hamid R. Bone marrow-derived cells contribute to pathogenesis of pulmonary arterial hypertension. Am J Resp Crit Care Med. 2016;193(8):898–909.Google Scholar
  149. Zhang Y, Yang Y, Chen L, Zhang J. Expression analysis of genes and pathways associated with liver metastases of the uveal melanoma. BMC Med Genet. 2014;15:29.PubMedPubMedCentralCrossRefGoogle Scholar
  150. Zopf DA, Neves LAA, Nikula KJ, Huang J, Senese PB, Gralinski MR. C-122, a novel antagonist of serotonin receptor 5-HT(2B), prevents monocrotaline-induced pulmonary arterial hypertension in rats. Eur J Pharmacol. 2011;670(1):195–203.PubMedPubMedCentralCrossRefGoogle Scholar
  151. Zsippai A, Szabó DR, Szabó PM, Tömböl Z, Bendes MR, Nagy Z, Igaz P. mRNA and microRNA expression patterns in adrenocortical cancer. Am J Cancer Res. 2011;1(5):618–28.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Luc Maroteaux
    • 1
  • Anne Roumier
    • 1
  • Stéphane Doly
    • 1
  • Silvina Laura Diaz
    • 1
  • Arnauld Belmer
    • 2
  1. 1.Université Pierre et Marie Curie, Institut du Fer à MoulinParisFrance
  2. 2.Institute of Health and Biomedical Innovation (IHBI)Queensland University of Technology (QUT)BrisbaneAustralia